Department of Hematology, Vall d'Hebron Barcelona Hospital Campus, Vall d'Hebron Institute of Oncology, Barcelona, Spain.
MLL Munich Leukemia Laboratory, Munich, Germany.
Blood. 2024 Oct 17;144(16):1722-1731. doi: 10.1182/blood.2024023840.
Mutations in the TP53 gene, particularly multihit alterations, have been associated with unfavorable clinical features and prognosis in patients diagnosed with myelodysplastic syndrome (MDS). Despite this, the role of TP53 gene aberrations in MDS with isolated deletion of chromosome 5 [MDS-del(5q)] remains unclear. This study aimed to assess the impact of TP53 gene mutations and their allelic state in patients with MDS-del(5q). To that end, a comprehensive analysis of TP53 abnormalities, examining both TP53 mutations and allelic imbalances, in 682 patients diagnosed with MDS-del(5q) was conducted. Twenty-four percent of TP53-mutated patients exhibited multihit alterations, whereas the remaining patients displayed monoallelic mutations. TP53-multihit alterations were predictive of an increased risk of leukemic transformation. The impact of monoallelic alterations was dependent on the variant allele frequency (VAF); patients with TP53-monoallelic mutations and VAF <20% exhibited behavior similar to TP53 wild type, and those with TP53-monoallelic mutations and VAF ≥20% presented outcomes equivalent to TP53-multihit patients. This study underscores the importance of considering TP53 allelic state and VAF in the risk stratification and treatment decision-making process for patients with MDS-del(5q).
TP53 基因突变,特别是多打击改变,与骨髓增生异常综合征(MDS)患者的不良临床特征和预后相关。尽管如此,TP53 基因异常在孤立性 5 号染色体缺失的 MDS(MDS-del(5q))中的作用仍不清楚。本研究旨在评估 TP53 基因突变及其等位状态在 MDS-del(5q)患者中的影响。为此,对 682 例 MDS-del(5q)患者进行了全面的 TP53 异常分析,包括 TP53 突变和等位基因失衡的检测。24%的 TP53 突变患者表现出多打击改变,而其余患者表现为单等位基因突变。TP53 多打击改变预测白血病转化风险增加。单等位基因突变的影响取决于变异等位基因频率(VAF);TP53 单等位基因突变且 VAF<20%的患者表现与 TP53 野生型相似,而 TP53 单等位基因突变且 VAF≥20%的患者与 TP53 多打击患者的结果相当。本研究强调了在 MDS-del(5q)患者的风险分层和治疗决策过程中考虑 TP53 等位基因状态和 VAF 的重要性。